导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -3.26% | 3100/4773 |
| 近一周 | -1.91% | 869/5462 |
| 近一月 | -1.88% | 1075/5421 |
| 近一季 | -1.49% | 1015/5209 |
| 近半年 | -1.33% | 1554/4920 |
| 近一年 | -0.05% | 2655/4366 |
| 近两年 | 36.41% | 2039/2954 |
| 近三年 | 23.33% | 1351/2253 |
| 成立以来 | 44.41% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-5.94% 3977/4961 |
6.63% 2812/5312 |
- - |
- - |
| 2025 | 16.07% 2490/4813 |
-0.26% 2159/3635 |
2.75% 1387/4076 |
10.63% 3265/4524 |
2.38% 974/4813 |
| 2024 | 17.88% 641/3463 |
3.22% 611/2808 |
-0.23% 712/3014 |
16.28% 1491/3129 |
-1.57% 1750/3463 |
| 2023 | -7.94% 964/2656 |
1.15% 1629/2280 |
-4.10% 1047/2385 |
1.55% 300/2515 |
-6.55% 1824/2655 |
| 2022 | -16.79% 515/2207 |
-10.80% 428/1919 |
6.21% 751/2016 |
-13.42% 901/2113 |
1.45% 1262/2208 |
| 2021 | -7.96% 1044/1822 |
-2.81% 706/1255 |
0.22% 1107/1330 |
-7.70% 1077/1466 |
2.38% 608/1822 |
| 2020 | 18.16% 747/1250 |
-11.97% 864/1028 |
9.76% 782/1067 |
9.70% 632/1164 |
11.48% 537/1184 |
| 2019 | 29.16% 510/1092 |
18.27% 641/754 |
4.03% 40/804 |
-0.10% 576/850 |
5.07% 753/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 工银上证50ETF联接A VS. 长安沪深300非周期A(740101) |